Compare Cassava Sciences Inc (FLNA) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs TotalEnergies SE — how do they compare? Cassava Sciences Inc trades at $0.81 (market cap $39.40M), while TotalEnergies SE trades at $87.82 (market cap $191.82B). The key difference: TotalEnergies SE is far larger — about 4868.5× Cassava Sciences Inc's market cap, and TotalEnergies SE pays a 4.93% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and TotalEnergies SE for 90 Days on average.
| FLNA | TTE | |
|---|---|---|
Market Cap | $39.40M | $191.82B |
Volume | 759,018 | 3,311,339 |
Sector | Health | Energy |
52-Week High | $4.64 | $93.60 |
52-Week Low | $0.68 | $57.39 |
Typical Hold Time | 37 Days | 90 Days |
Enterprise Value | -$43.28M | $222.81B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
TotalEnergies (TTE) trades at $84.23, up 0.3% on the day, with a bearish technical signal from moving averages but recent earnings beats in Q1 and Q2 2026. The stock trades at attractive valuations with a P/E of 10.77 and P/S of 0.96, supported by a 9.08% net income margin. Recent news highlights a $10 billion investment plan in Argentina and a strategic focus on boosting cash flow and dividends through 2030.
The outlook is positive given analyst consensus targets of $95.33 and strong buy ratings (55.88%), though risks include declining revenue trends from 2022-2025 and exposure to oil price volatility. The company's shareholder returns via dividends and buybacks provide support, but investors should monitor execution of growth initiatives amid energy market uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
